摘要
目的:探讨2型糖尿病(DM)患者凝血、抗凝及纤溶活性的改变及其临床意义。方法:应用酶联免疫吸附双抗体夹心法及发色底物法测定2型DM患者血中凝血酶原片段1+2(F1+2)、可溶性纤维蛋白单体复合物(SFMC)、抗凝血酶(AT)、组织型纤溶酶原激活剂(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)活性。纤维蛋白原(Fbg)测定为Claus法。结果:①2型DM患者的Fbg、F1+2、SFMC、及PAI-1较正常对照组有显著性增高,AT和t-PA表现为显著性降低(P<0.05);②DM有并发症组与DM无并发症组相比较,上述凝血、抗凝及纤溶各指标间亦差异有统计学意义(P<0.05);③各指标改变的幅度随病变的程度增加而加重。结论:2型DM患者的凝血活性亢进、抗凝和纤溶活性降低,导致凝血-纤溶功能紊乱,表现为血液高凝状态,当DM患者有并发症存在时更为明显。为临床上对糖尿病患者使用抗凝剂及抗血小板药物治疗提供了理论依据。
Objective：To explore the changes and clinical significance in coagulation,anti-coagulation and fibrinolysis system in patients with type 2 diabetes mellitus（DM）.Method：Plasma prothrombin fragment 1＋2（F1＋2）,soluble fibrinomonomer compound（SFMC）,antithrombin-Ⅲ（AT-Ⅲ）,Fibrogen（Fib）,tissue-type plasminogen activator（t-PA）and plasminogen activator inhibitor-1（PAI-1）levels were determined by ELISA and chromogenic assay respectively in 35 normal control group,56 patients with type 2 DM.Result：In DM group plasma levels of F1＋2,SFMC,Fib and PAI-1 were significantly higher than those of control group,but AT-Ⅲ and t-PA levels was significantly lower than those of control group.There was a significant difference between single DM group and DM with complication group.Conclusion：There was endothelial damages in patients with type 2 DM.The levels of plasma vWF 、6-K-PGF1αand PAI-1 may be used to surveillance type 2 DM.It would be important for the diagnosis and therapy of high coagulation state in DM patients.
出处
《临床血液学杂志（输血与检验）》
CAS
2010年第1期84-85,共2页
Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
关键词
2型糖尿病
凝血
抗凝
纤溶
patients with type 2 diabetes mellitus
blood coagulation
anti-coagulation
fibrinolysis system
